Omega-3 supplier BASF will continue to produce the API for Amarin, as well as its competitor GlaxoSmithKline, despite an FDA panel saying that Amarin’s drug should not be approved for a broader population.
Last week, BASF officially opened a pharmaceutical grade omega-3 active pharmaceutical ingredient (API) facility on the Isle of Lewis, Scotland that it gained with the acquisition of Equateq earlier this year.
A facility operated by fatty acid specialist Equateq on the island of Lewis in Scotland has met with UK good manufacturing practice (GMP) standards for the production of lipid-based APIs for the drug industry.
Danish firm Pronova BioPharma announced this morning that it is to
double manufacturing capacity for its marine-derived active
pharmaceutical ingredient (API), following increased demand for its
omega-3 based drug.
New anti-breast cancer drugs could be developed after latest
research suggested that Omega-3, a fatty acid found in oily fish,
could be combined with an anaesthetic to reduce the ability of
breast cancer cells to develop into malignant...